DCCA
PACB icon

D.C. Capital Advisors’s Pacific Biosciences PACB Stock Holding History

D.C. Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$356K – 27
2017
Q2 		$356K Buy
+100,000
New +$403K 0.25% 23
2017
Q1 		– Sell
-50,000
Closed -$190K – 25
2016
Q4 		$190K Buy
+50,000
New +$363K 0.11% 23

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

D.C. Capital Advisors's PACB Position: Q3 2017 in Review

D.C. Capital Advisors sold out of Pacific Biosciences (PACB) in Q3 2017, closing a stake of 100,000 shares — an estimated $356K sold.

D.C. Capital Advisors first reported a position in PACB in Q4 2016 and held it in 2 quarters. The position peaked at $356K in Q2 2017. 98 funds tracked by Wall St. Rank hold PACB as of Q3 2017.

  • D.C. Capital Advisors reported no remaining Pacific Biosciences position as of Q3 2017 after selling out during the quarter.
  • D.C. Capital Advisors sold 100,000 Pacific Biosciences shares in Q3 2017, an estimated $356K.
  • D.C. Capital Advisors first reported a position in Pacific Biosciences in Q4 2016 and held it in 2 quarters.
  • D.C. Capital Advisors's Pacific Biosciences position peaked at $356K in Q2 2017.
  • 98 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2017.

Based on D.C. Capital Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.